论文部分内容阅读
目的探讨拉米夫定治疗100例乙肝患者的临床疗效。方法本院于2006年11月至2008年6月对100例乙肝患者采用拉米夫定治疗,并与采用一般保肝、利胆、退黄等方法治疗的对照组进行疗效比较。结果取得良好的临床疗效,在治疗开始12个月,本文对两组患者的各项生化指标进行检测并统计分析发现治疗组的ALT复常率达、HBeAg阴转率、HBeAb阳转率、HBVDNA阴转率均明显高于对照组相应的生化指标,且差异具有统计学意义(P<0.05)。结论拉米夫定使用方便、安全,是目前惟一口服有效的抗病毒药,它给乙肝的治疗带来突破,它对临床治疗乙肝有着重要的意义。
Objective To investigate the clinical efficacy of lamivudine in treating 100 cases of hepatitis B patients. Methods The hospital from November 2006 to June 2008 on 100 cases of hepatitis B patients treated with lamivudine, and with the general liver, gallbladder, yellow and other methods of treatment of the control group were compared. The results achieved good clinical efficacy, at the beginning of 12 months of treatment, the two groups of biochemical indicators were detected and statistical analysis found that the treatment group ALT normalization rate, HBeAg negative conversion rate, HBeAb positive conversion rate, HBVDNA Negative conversion rate were significantly higher than the control group corresponding biochemical indicators, and the difference was statistically significant (P <0.05). Conclusions Lamivudine is convenient and safe to use. It is the only oral and effective antiviral drug. It brings a breakthrough in the treatment of hepatitis B, which is of great significance for the clinical treatment of hepatitis B.